EUCTR2017-001489-53-PL进行中（未招募）1 期
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Subjects with Active Systemic Lupus Erythematosus - LOTUS
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Between 16 (unless restricted by local requirements) and 75 years of age, inclusive.
- •Diagnosis of SLE made or confirmed by a physician experienced in the treatment of SLE.
- •Documented medical history (ie, met at least 1 of the bulleted criteria below) that subject met the SLICC classification criteria for SLE at least 3 months prior to first dose of study agent:
- •- Met a total of at least 4 SLICC criteria including at least 1 clinical and at least 1 immunologic.
- •- Had a diagnosis of lupus nephritis, confirmed by renal biopsy and at least 1 of the following autoantibodies: ANA or anti-dsDNA.
- •At least 1 well-documented unequivocally positive test in medical history and detected during screening, for at least 1 of the following autoantibodies: ANA, anti-dsDNA, and/or anti-Smith.
- •Have at least 1 BILAG A and/or 2 BILAG B domain scores observed during screening.
- •Have a CLASI activity score of at least 4 or at least 4 joints with pain and signs of inflammation at screening or at Week 0, or both.
- •Demonstrate active disease based on SLEDAI-2K score =6 observed during screening. Must also have SLEDAI-2K =4 for clinical features (ie, SLEDAI-2K score excluding headache, and laboratory abnormalities) present at Week 0 prior to randomization.
- •Must be receiving one or more of the following protocol-permitted, systemic standard-of-care treatments:
- •a) Oral glucocorticoids (average daily dose =20 mg of prednisone or equivalent) for =6 weeks and at a stable dose =4 weeks prior to first dose of study agent.
- •- If currently not using oral glucocorticoids, must not have received them for =6 weeks prior to the first dose of study agent.
- •b) Antimalarials for =12 weeks and at a stable dose for =6 weeks prior to first dose of study agent
- •c) If using one or more of the following immunomodulatory drugs, must be receiving for =12 weeks and be on a stable dose for =6 weeks prior to first dose of study agent:
- •-MMF =2 g/day
- •-MPA =1.5 g/day
- •-AZA /6-MP =2 mg/kg/day; up to 100 mg/day for subjects weighing =50 kg
- •-Oral MTX =25 mg/Week or SC or intramuscular (IM) MTX =20 mg/Week with concomitant folic acid or folinic acid.
- •If the subject is using concomitantly 2 or more of the immunomodulatory drugs listed above (MMF, MPA, AZA, 6-MP, MTX), the suitability of the subject to participate in the study must be discussed with the medical monitor and/or sponsor before the subject is randomized.
- •Before randomization, a woman must be either:
- •a. Not of childbearing potential, or
- •b. Of childbearing potential:
- •-Practicing a highly effective method of contraception
- •-Agrees to remain on a highly effective method of contraception throughout the study and for at least 16 weeks after the last dose of study agent.
- •A woman of childbearing potential must have a negative urine pregnancy tests
- •beta-hCG obtained during screening and at Week 0 before the first dose of study agent.
- •A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for 4 months after receiving the last dose of study agent.
- •A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control.
- •A man who is sexually active with a woman who is pregnant must use a condom and all men must not donate sperm during the study and for 20 weeks after receiving the last dose of study agent.
- •Subjects must have laboratory test results within the
排除标准
- •Has any unstable or progressive manifestation of SLE that is likely to warrant escalation in therapy beyond permitted background medications. Subjects requiring renal hemodialysis or peritoneal dialysis are also excluded •Has other inflammatory disease that might confound the evaluations of efficacy, including but not limited to rheumatoid arthritis (RA), PsA, RA/lupus overlap, psoriasis, Crohn's disease, or active Lyme disease •Is pregnant, nursing, or planning a pregnancy or planning to father a child while enrolled in the study or within 4 months after receiving the last administration of study agent •Has received systemic immunomodulatory agents other than those described in inclusion criteria within 3 months prior to the first dose of study agent •Has used oral cyclophosphamide within 90 days or IV cyclophosphamide within 180 days of starting screening •Exclusions for treatment with B-cell targeted therapies*: a.Treatment with a single B-cell targeted therapy within 3 months prior to first dose of study agent. b.Treatment with >1 previous B-cell targeted therapy within 6 months prior to first dose of study agent. c.Treatment with B-cell depleting therapy within 12 months prior to first dose of study agent, or have evidence of continued B-cell depletion following such therapy *If a subject has received one or more B-cell targeted therapies, the length of time required before administering the first dose of study agent should be whichever is the longest applicable washout period. •Has ever received ustekinumab •Has received prior immunomodulatory biologic therapy not described in Section 8.1.7 of protocol less than 5 half-lives or 3 months, whichever is longer, prior to first dose of the study agent. •Has received ACTH administered by injection within 1 month prior to the first administration of study agent •Has received topical cream/ointment preparations of cyclosporine A, high-potency topical glucocorticoids, or other topical immunomodulatory agents within 4 weeks prior to the first administration of study agent •Is currently receiving venom immunotherapy •Subjects likely to require multiple courses of systemic steroids for reasons other than SLE •Has received epidural, IV, IM, intra-articular (IA), intrabursal, or intralesional admin of glucocorticoids within 6 weeks prior to the first administration of study agent •BCG vaccination within 12 months of screening •Live virus or live bacterial vaccination within 16 weeks prior to the first administration of study agent •History of active granulomatous infection, including histoplasmosis, or coccidioidomycosis •Chest radiograph within 3 months prior to the first dose that shows an abnormality suggestive of a malignancy or current active infection, including TB •A nontuberculous mycobacterial infection or opportunistic infection •A history of, or ongoing, chronic or recurrent infectious disease •History of HIV antibody positive, or tests positive for HIV at screening •Hepatitis B infection. Subjects must undergo screening for hepatitis B virus •Seropositive for antibodies to hepatitis C virus (HCV), unless has 2 negative HCV RNA test results 6 months apart prior to screening and has a third negative HCV RNA test result at screening •Has experienced a recent single dermatomal herpes zoster eruption within the past 4 months. Has ever had multi-dermatomal herpes zoster or CNS zoster infection
- •Within 2 months prior to first administration of study agent, has had a serious infection,
研究者
相似试验
进行中（未招募）
1 期
A Clinical Study of Rituximab with Ibrutinib Compared to Rituxumab Alone, and Subsequently of Ibrutinib Alone Compared to Placebo in Treatment Naïve Subjects with Follicular LymphomaMedDRA version: 24.0Level: LLTClassification code 10029473Term: Nodular (follicular) lymphomaSystem Organ Class: 100000004864Follicular lymphomaEUCTR2016-003202-14-PTPharmacyclics LLC440
进行中（未招募）
不适用
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalfa Monoclonal Antibody, Administered Intravenously, in Subjects with Active Rheumatoid Arthritis Despite Methotrexate TherapyEUCTR2005-003232-21-LVCentocor B.V.625
进行中（未招募）
1 期
A Study of the Efficacy and Safety of Guselkumab in Participants with Active Lupus NephritisEUCTR2018-003155-38-PLJanssen-Cilag International NV60
进行中（未招募）
1 期
A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus ErythematosusSystemic Lupus ErythematosusEUCTR2014-005000-19-DEJanssen-Cilag International N.V.134
进行中（未招募）
1 期
Phase 1b/2a Study of WVE-004 in Patients with C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)Amyotrophic Lateral Sclerosis and Frontotemporal DementiaMedDRA version: 21.1Level: PTClassification code 10002026Term: Amyotrophic lateral sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 21.1Level: PTClassification code 10068968Term: Frontotemporal dementiaSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-005193-94-SEWave Life Sciences UK Limited42